A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines

[1]  A. Benito,et al.  The nuclear transport capacity of a human-pancreatic ribonuclease variant is critical for its cytotoxicity , 2011, Investigational New Drugs.

[2]  M. V. Nogués,et al.  A human ribonuclease induces apoptosis associated with p21WAF1/CIP1 induction and JNK inactivation , 2011, BMC Cancer.

[3]  L. Rakić,et al.  Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil , 2010, Investigational New Drugs.

[4]  W. Ardelt,et al.  Activity of Anti-Tumor Endoribonucleases, Onconase (ranpirnase) and R-Amphinase in Chronic Lymphocytic Leukemia , 2008 .

[5]  W. Ardelt,et al.  Ex Vivo Cytotoxic Activity of Endoribonucleases, Onconase (ranpirnase) and R-Amphinase, against Acute Myeloblastic Leukemia Cells , 2008 .

[6]  A. Stavrovskaya,et al.  Transport proteins of the ABC family and multidrug resistance of tumor cells , 2008, Biochemistry (Moscow).

[7]  W. Ardelt,et al.  Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes. , 2008, Current pharmaceutical biotechnology.

[8]  M. Ueno,et al.  Involvement of MDR1 function in proliferation of tumour cells. , 2007, Journal of biochemistry.

[9]  A. Segura‐Carretero,et al.  Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells , 2007, BMC Cancer.

[10]  A. Benito,et al.  A cytotoxic ribonuclease variant with a discontinuous nuclear localization signal constituted by basic residues scattered over three areas of the molecule. , 2006, Journal of molecular biology.

[11]  A. Paradiso,et al.  Cyclohexylpiperazine derivative PB28, a σ2 agonist and σ1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer , 2006, Molecular Cancer Therapeutics.

[12]  T. Ozben.  Mechanisms and strategies to overcome multiple drug resistance in cancer , 2006, FEBS letters.

[13]  L. Rakić,et al.  Induced Resistance in the Human Non Small Cell Lung Carcinoma (NCI-H460) Cell Line In Vitro by Anticancer Drugs , 2006, Journal of chemotherapy.

[14]  D. Sidransky,et al.  Ribonucleases as a Novel Pro-Apoptotic Anticancer Strategy: Review of the Preclinical and Clinical Data for Ranpirnase , 2005, Cancer investigation.

[15]  E. Cummins,et al.  c-Jun NH2-Terminal Kinase Activation Contributes to Hypoxia-Inducible Factor 1α–Dependent P-Glycoprotein Expression in Hypoxia , 2004, Cancer Research.

[16]  Y. Hathout,et al.  Highly altered protein expression profile in the adriamycin resistant MCF-7 cell line. , 2004, Journal of proteome research.

[17]  A. Benito,et al.  Quantitative analysis, using MALDI-TOF mass spectrometry, of the N-terminal hydrolysis and cyclization reactions of the activation process of onconase. , 2004, European journal of biochemistry.

[18]  J. Menéndez,et al.  Inhibition of Tumor-associated Fatty Acid Synthase Hyperactivity Induces Synergistic Chemosensitization of HER-2/neu-Overexpressing Human Breast Cancer Cells to Docetaxel (taxotere) , 2004, Breast Cancer Research and Treatment.

[19]  M. Lacroix,et al.  Relevance of Breast Cancer Cell Lines as Models for Breast Tumours: An Update , 2004, Breast Cancer Research and Treatment.

[20]  S. Ledoux,et al.  Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. , 2003, Cancer research.

[21]  T. Hagve,et al.  The cyclosporin PSC 833 increases survival and delays engraftment of human multidrug-resistant leukemia cells in xenotransplanted NOD-SCID mice , 2002, Leukemia.

[22]  Johnson Ra,et al.  Transcription of the multidrug resistance gene MDR1: a therapeutic target. , 2001 .

[23]  J. Li,et al.  Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line , 2001, Breast Cancer Research.

[24]  I. Roninson,et al.  Effects of the multidrug transporter P-glycoprotein on cellular responses to ionizing radiation. , 2000, Cancer research.

[25]  E. Mombelli,et al.  Production of engineered human pancreatic ribonucleases, solving expression and purification problems, and enhancing thermostability. , 1999, Protein expression and purification.

[26]  B Fisher,et al.  erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. , 1998, Journal of the National Cancer Institute.

[27]  R. Raines,et al.  Ribonuclease A variants with potent cytotoxic activity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[28]  H. Rugstad,et al.  Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein. , 1998, British Journal of Cancer.

[29]  R. Johnstone,et al.  The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  W. K. Roberts,et al.  Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. , 1997, Biochemistry.

[31]  B. Ogretmen,et al.  Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells , 1997, Oncogene.

[32]  T. Chambers,et al.  Role of the Stress-activated/c-Jun NH2-terminal Protein Kinase Pathway in the Cellular Response to Adriamycin and Other Chemotherapeutic Drugs* , 1996, The Journal of Biological Chemistry.

[33]  D. Newton,et al.  Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease. , 1996, Journal of the National Cancer Institute.

[34]  C. Pace,et al.  How to measure and predict the molar absorption coefficient of a protein , 1995, Protein science : a publication of the Protein Society.

[35]  M. Volm.  P-glycoprotein associated expression of c-fos and c-jun products in human lung carcinomas. , 1993, Anticancer research.

[36]  M. Ikeguchi,et al.  Structural and functional analyses of the promoter of the murine multidrug resistance gene mdr3/mdr1a reveal a negative element containing the AP-1 binding site. , 1991, DNA and cell biology.

[37]  Berenbaum Mc.  What is synergy? , 1989, Pharmacological reviews.

[38]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[39]  R. Chandra,et al.  Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. , 2006, Cancer research.

[40]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[41]  K. Scotto,et al.  Transcription of the multidrug resistance gene MDR1: a therapeutic target. , 2001, Molecular interventions.

[42]  V. Vasandani,et al.  Reversible nephrotoxicity of onconase and effect of lysine pH on renal onconase uptake , 1999, Cancer Chemotherapy and Pharmacology.

[43]  M. Berenbaum.  What is synergy? , 1989, Pharmacological reviews.